Literature DB >> 22094073

Implantable cardioverter-defibrillator longevity under clinical circumstances: an analysis according to device type, generation, and manufacturer.

Joep Thijssen1, C Jan Willem Borleffs, Johannes B van Rees, SumChe Man, Mihály K de Bie, Jeroen Venlet, Enno T van der Velde, Lieselot van Erven, Martin J Schalij.   

Abstract

BACKGROUND: One of the major drawbacks of implantable cardioverter-defibrillator (ICD) treatment is the limited device service life. Thus far, data concerning ICD longevity under clinical circumstances are scarce. In this study, the ICD service life was assessed in a large cohort of ICD recipients.
OBJECTIVE: To assess the battery longevity of ICDs under clinical circumstances.
METHODS: All patients receiving an ICD in the Leiden University Medical Center were included in the analysis. During prospectively recorded follow-up visits, reasons for ICD replacement were assessed and categorized as battery depletion and non-battery depletion. Device longevity and battery longevity were calculated. The impact of device type, generation, manufacturer, the percentage of pacing, the pacing output, and the number of shocks on the battery longevity was assessed.
RESULTS: Since 1996, 4673 ICDs were implanted, of which 1479 ICDs (33%) were replaced. Mean device longevity was 5.0 ± 0.1 years. A total of 1072 (72%) ICDs were replaced because of battery depletion. Mean battery longevity of an ICD was 5.5 ± 0.1 years. When divided into different types, mean battery longevity was 5.5 ± 0.2 years for single-chamber ICDs, 5.8 ± 0.1 for dual-chamber ICDs, and 4.7 ± 0.1 years for cardiac resynchronization therapy-defibrillators (P <.001). Devices implanted after 2002 had a significantly better battery longevity as compared with devices implanted before 2002 (5.6 ± 0.1 years vs 4.9 ± 0.2 years; P <.001). In addition, large differences in battery longevity between manufacturers were noted (overall log-rank test, P <.001).
CONCLUSIONS: The majority of ICDs were replaced because of battery depletion. Large differences in longevity exist between different ICD types and manufacturers. Modern ICD generations demonstrated improved longevity.
Copyright © 2012 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22094073     DOI: 10.1016/j.hrthm.2011.11.022

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  21 in total

1.  Significant differences in the expected versus observed longevity of implantable cardioverter defibrillators (ICDs).

Authors:  Tali Shafat; Yael Baumfeld; Victor Novack; Yuval Konstantino; Guy Amit
Journal:  Clin Res Cardiol       Date:  2012-07-14       Impact factor: 5.460

Review 2.  Electrical cardioversion of patients with implanted pacemaker or cardioverter-defibrillator: results of a survey of german centers and systematic review of the literature.

Authors:  J Lüker; A Sultan; T Plenge; J van den Bruck; C-H Heeger; S Meyer; K Mischke; R R Tilz; D Vollmann; G Nölker; B Schäffer; S Willems; D Steven
Journal:  Clin Res Cardiol       Date:  2017-11-18       Impact factor: 5.460

Review 3.  Clinical experience with subcutaneous implantable cardioverter-defibrillators.

Authors:  Geoffrey F Lewis; Michael R Gold
Journal:  Nat Rev Cardiol       Date:  2015-04-21       Impact factor: 32.419

4.  The mismatch between patient life expectancy and the service life of implantable devices in current cardioverter-defibrillator therapy: a call for larger device batteries.

Authors:  Jörg Neuzner
Journal:  Clin Res Cardiol       Date:  2015-02-19       Impact factor: 5.460

5.  "Real life" longevity of implantable cardioverter-defibrillator devices.

Authors:  Antonis S Manolis; Themistoklis Maounis; Spyridon Koulouris; Vassilios Vassilikos
Journal:  Clin Cardiol       Date:  2017-05-22       Impact factor: 2.882

Review 6.  Economic evaluations of implantable cardioverter defibrillators: a systematic review.

Authors:  Lidia García-Pérez; Pilar Pinilla-Domínguez; Antonio García-Quintana; Eduardo Caballero-Dorta; F Javier García-García; Renata Linertová; Iñaki Imaz-Iglesia
Journal:  Eur J Health Econ       Date:  2014-10-17

7.  The Effect of Chronic Kidney Disease on Mortality with Cardiac Resynchronization Therapy.

Authors:  David D Daly; Anbukarasi Maran; J Madison Hyer; Frederick Funke; Ashley Waring; Frank A Cuoco; J Lacy Sturdivant; Robert B Leman; Michael R Gold
Journal:  Pacing Clin Electrophysiol       Date:  2016-06-07       Impact factor: 1.976

8.  Association of single- vs dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention.

Authors:  Pamela N Peterson; Paul D Varosy; Paul A Heidenreich; Yongfei Wang; Thomas A Dewland; Jeptha P Curtis; Alan S Go; Robert T Greenlee; David J Magid; Sharon-Lise T Normand; Frederick A Masoudi
Journal:  JAMA       Date:  2013-05-15       Impact factor: 56.272

Review 9.  Adverse events following implantable cardioverter defibrillator implantation: a systematic review.

Authors:  Rebecca Persson; Amy Earley; Ann C Garlitski; Ethan M Balk; Katrin Uhlig
Journal:  J Interv Card Electrophysiol       Date:  2014-06-20       Impact factor: 1.900

10.  Characteristics and outcomes of patients receiving new and replacement implantable cardioverter-defibrillators: results from the NCDR.

Authors:  Daniel B Kramer; Kevin F Kennedy; Peter A Noseworthy; Alfred E Buxton; Mark E Josephson; Sharon-Lise Normand; John A Spertus; Peter J Zimetbaum; Matthew R Reynolds; Susan L Mitchell
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.